Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study Post published:October 21, 2022 Post category:Press Release
Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics Post published:October 19, 2022 Post category:Press Release
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia Post published:October 11, 2022 Post category:Press Release
Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12 Post published:October 6, 2022 Post category:Press Release
Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology Post published:October 4, 2022 Post category:Press Release
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option Post published:October 1, 2022 Post category:Press Release
Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock Post published:September 28, 2022 Post category:Press Release
Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq Post published:September 15, 2022 Post category:Press Release
Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine Post published:July 28, 2022 Post category:Press Release
Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients Post published:July 15, 2022 Post category:Press Release